Completed PHASE1 INTERVENTIONAL 1-arm NCT01815086

Radioimmunoimaging of Light Chain (AL) Amyloidosis

Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4

Sponsor: University of Tennessee

Conditions AL Amyloidosis

Interventions Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)

Updated 6 times since 2017 Last updated: Sep 17, 2013 Started: Dec 31, 2008 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01815086, this PHASE1 trial focuses on AL Amyloidosis and remains completed. Sponsored by University of Tennessee, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Tennessee

Data source: University of Tennessee

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Knoxville, United States